Literature DB >> 6270192

Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion from human corticotroph adenoma cells in vitro.

M Ishibashi, T Yamaji.   

Abstract

In an attempt to delineate the mechanism and the site of action of cyproheptadine and dopaminergic agonists as well as hormones including thyrotropin-releasing hormone (TRH) and hydrocortisone, the effects of these substances on ACTH secretion from corticotroph adenoma cells in culture were examined. Dispersed cells of pituitary adenomas obtained at surgery from four patients with Nelson's syndrome and one subject with Cushing's disease formed a monolayer and actively secreted ACTH into the medium. When TRH (0.1 microM) was added to the medium, a significant increase in ACTH secretion was demonstrated by adenoma cells from two patients who responded to TRH preoperatively. Moreover, a dose-response relationship between TRH concentrations and ACTH secretion was observed. Incubation of cells with cyproheptadine (1 or 0.1 microM) resulted in a significant decrease in ACTH release, and inhibited stimulation produced by TRH in one experiment. This effect of cyproheptadine was blocked when equimolar concentrations of serotonin was coincubated, whereas serotonin by itself did not affect ACTH secretion. Dopamine (0.1 microM) lowered ACTH accumulation in the medium, which was blocked by the addition of haloperidol. When hydrocortisone was added to the culture, dose-dependent suppression of ACTH secretion was demonstrated. TRH at an equimolar concentration reversed this effect, but, failed to overcome the inhibition induced by a higher concentration of hydrocortisone in cells from one adenoma studied. Cultured normal corticotrophs obtained from a patient with metastatic breast cancer, on the other hand, did not show any response to these substances, except for hydrocortisone. We suggest that TRH, cyproheptadine, dopamine affect ACTH secretion in patients with ACTH-producing pituitary adenomas by their direct action on the adenoma.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6270192      PMCID: PMC370889          DOI: 10.1172/jci110324

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Lack of effect of antiserotoninergic and/or dopaminergic treatment in patients with pituitary-dependent Cushing's syndrome.

Authors:  B Ambrosi; M Gaggini; F Secchi; G Faglia
Journal:  Horm Metab Res       Date:  1979-04       Impact factor: 2.936

2.  Serotonin regulation of ACTH secretion.

Authors:  D T Krieger
Journal:  Ann N Y Acad Sci       Date:  1977-10-28       Impact factor: 5.691

3.  More on cyproheptadine in Cushing's disease.

Authors: 
Journal:  N Engl J Med       Date:  1977-03-10       Impact factor: 91.245

4.  Letter: Cyproheptadine for pituitary disorders.

Authors: 
Journal:  N Engl J Med       Date:  1976-08-12       Impact factor: 91.245

5.  Radioimmunoassay of ACTH in plasma.

Authors:  S A Berson; R S Yalow
Journal:  J Clin Invest       Date:  1968-12       Impact factor: 14.808

6.  Effects of growth hormone release-inhibiting hormone and bromocryptine (CB 154) in states of abnormal pituitary-adrenal function.

Authors:  G Benker; K Hackenberg; B Hamburger; D Reinwein
Journal:  Clin Endocrinol (Oxf)       Date:  1976-03       Impact factor: 3.478

7.  Effect of thyrotropin-releasing hormone and bromoergocriptine on growth hormone and prolactin secretion in perfused pituitary adenoma tissues of acromegaly.

Authors:  M Ishibashi; T Yamaji
Journal:  J Clin Endocrinol Metab       Date:  1978-12       Impact factor: 5.958

8.  Cyproheptadine treatment of Nelson's syndrome: restoration of plasma ACTH circadian periodicity and reversal of response to TRF.

Authors:  D T Krieger; E M Condon
Journal:  J Clin Endocrinol Metab       Date:  1978-02       Impact factor: 5.958

9.  Lack of effect of bromocriptine on ACTH levels in patients with bilateral adrenalectomy for pituitary-dependent Cushing's syndrome.

Authors:  N O'Mullane; B Walker; J Jefferson; L Hipkin; M Diver; C Davis
Journal:  J Endocrinol Invest       Date:  1978-10       Impact factor: 4.256

10.  Effectiveness of cyproheptadine in decreasing plasma ACTH concentrations in Nelson's syndrome.

Authors:  D T Krieger; M Luria
Journal:  J Clin Endocrinol Metab       Date:  1976-11       Impact factor: 5.958

View more
  7 in total

Review 1.  Medical management of pituitary adenomas: structural and ultrastructural changes.

Authors:  Sylvia L Asa; Shereen Ezzat
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

2.  Cyproheptadine treatment in Cushing's disease.

Authors:  R Tanakol; F Alagöl; H Azizlerli; O Sandalci; T Terzioğlu; F Berker
Journal:  J Endocrinol Invest       Date:  1996-04       Impact factor: 4.256

3.  Cyproheptadine may act at the pituitary in Cushing's disease: evidence from CRF stimulation.

Authors:  J R Tucci; K J Nowakowski; I M Jackson
Journal:  J Endocrinol Invest       Date:  1989-03       Impact factor: 4.256

4.  Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.

Authors:  M Ishibashi; T Yamaji
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

5.  Neurophysin biosynthesis in vitro in oat cell carcinoma of the lung with ectopic vasopressin production.

Authors:  T Yamaji; M Ishibashi; S Katayama; A Itabashi; N Ohsawa; Y Kondo; Y Mizumoto; K Kosaka
Journal:  J Clin Invest       Date:  1981-12       Impact factor: 14.808

6.  Fingerprints of CNS drug effects: a plasma neuroendocrine reflection of D2 receptor activation using multi-biomarker pharmacokinetic/pharmacodynamic modelling.

Authors:  Willem J van den Brink; Dirk-Jan van den Berg; Floor E M Bonsel; Robin Hartman; Yin-Cheong Wong; Piet H van der Graaf; Elizabeth C M de Lange
Journal:  Br J Pharmacol       Date:  2018-08-31       Impact factor: 8.739

7.  TRH-induced secretion of adrenocorticotropin and cortisol in dogs with pituitary-dependent hypercortisolism.

Authors:  Tera Pijnacker; Marieke Knies; Sara Galac; Karin Sanders; Jan A Mol; Hans S Kooistra
Journal:  Vet Q       Date:  2018-12       Impact factor: 3.320

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.